Corbus Pharmaceuticals Holdings, Inc. — Q1 2022 Form 10-Q Summary
Business Context and Reporting Period
Corbus is a clinical-stage biotechnology company developing immune-modulating therapies for oncology, fibrosis, obesity, and related diseases. The filing covers the three months ended March 31, 2022, and was filed May 10, 2022. The company has not generated product-sales revenue and remains dependent on external financing.
- CRB-601: Anti-αvβ8 monoclonal antibody for solid tumors; an FDA investigational new drug submission was planned for the first half of 2023.
- CRB-602: Discovery-stage anti-αvβ6/αvβ8 antibody program for oncology and fibrosis.
- CB1 inverse agonists: Preclinical obesity and metabolic-disease program.
- Lenabasum: The Phase 3 dermatomyositis study failed to meet its primary endpoint. Corbus did not plan additional company-sponsored lenabasum studies and intended to seek licensing partners.
Financial Performance and Key Metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue from awards | $0 | $647,824 | Down 100% |
| Research and development expense | $3.3 million | $10.7 million | Down $7.4 million |
| General and administrative expense | $5.2 million | $5.3 million | Down $0.1 million |
| Total operating expenses | $8.5 million | $16.1 million | Down $7.5 million |
| Net loss | $9.4 million | $16.1 million | Improved by $6.6 million |
| Net loss per share | $0.08 | $0.14 | Improved |
| Net cash used in operating activities | $10.6 million | $21.8 million | Improved by $11.2 million |
- There was no meaningful operating margin because the company had no revenue in the quarter and reported an operating loss of $8.5 million.
- Other expense, net increased to $0.9 million from $0.7 million, primarily due to foreign-currency losses.
- Stock-based compensation was $1.6 million, compared with $2.6 million in Q1 2021.
- At March 31, 2022, cash and cash equivalents were $57.0 million, investments were $29.1 million, and restricted cash was $0.7 million. Total cash, investments, and restricted cash therefore totaled approximately $86.8 million based on the balance sheet and cash-flow disclosure.
- Current assets were $88.5 million and current liabilities were $15.1 million, producing working capital of approximately $73.4 million.
- Total debt consisted primarily of the K2 HealthVentures secured loan, with $20.0 million of principal outstanding, plus a $1.2 million final payment obligation. The balance-sheet carrying amount of long-term debt and current debt was approximately $18.9 million, net of discount.
Material Changes Versus the Prior Comparable Period
- Revenue from the Cystic Fibrosis Foundation award ended after the related research and development activities were completed; no future revenue was expected from that award.
- Research and development expense declined substantially, primarily because lenabasum clinical studies were completed or winding down. Management also cited lower compensation and data-analysis costs.
- Operating cash usage decreased significantly, reflecting lower expenses and changes in working capital.
- Q1 2021 included approximately $60.7 million of gross proceeds from an at-the-market equity offering and approximately $0.9 million from option exercises; no comparable equity financing proceeds were received in Q1 2022.
- Common shares outstanding increased modestly to 125.3 million at March 31, 2022, from 125.2 million at December 31, 2021.
- Investments declined from $72.6 million at December 31, 2021 to $29.1 million at March 31, 2022, primarily reflecting maturities and sales of marketable securities.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected expenses to continue declining in 2022 but anticipated continued significant operating losses and the need for additional financing.
- The filing states that cash, cash equivalents, and investments of approximately $86.1 million would fund operations for at least twelve months from filing; the MD&A separately states that approximately $86.1 million would fund operations into the first quarter of 2024 based on current planned expenditures. The filing text does not clearly reconcile these differing liquidity estimates.
- Future financing could include equity, debt, collaborations, or grants. The company warned that financing may be unavailable or dilutive and that insufficient funds could require delaying, reducing, or discontinuing clinical and preclinical programs.
- Because public float was below $75 million, the company stated that the SEC “baby shelf” rules limited shelf offerings to approximately $22.7 million during any twelve-month period while the public float remained below that threshold.
- The K2 loan matures August 1, 2024, bears interest at a variable rate that was 8.75% at March 31, 2022, is secured by substantially all company assets, and contains financial and non-financial covenants. Corbus reported compliance with those covenants.
- Venn Therapeutics filed an amended complaint alleging trade-secret misappropriation, breach of contract, and related claims involving CRB-601. Corbus moved to dismiss and stated that it considered the claims meritless, but no assurance was given regarding the outcome.
- License agreements for the company’s pipeline include potential milestone obligations of up to $18.4 million per Jenrin compound, $53.0 million under the Milky Way agreement, and $153.0 million under the UCSF agreement, plus royalties. No milestone payments had been made under these agreements as of March 31, 2022.
- The company had an accumulated deficit of approximately $359.2 million and stated that it may never achieve profitability.
Important Facts for Investors to Verify
- Reconcile the filing’s differing liquidity and runway figures, including the approximately $86.1 million versus $86.8 million cash-and-investments amounts.
- Assess the timing, probability, and financing requirements for the planned CRB-601 IND submission and development of CRB-602 and the CB1 program.
- Review the Venn litigation, including any developments concerning the requested preliminary injunction and potential impact on CRB-601.
- Confirm the company’s ability to raise capital under the baby shelf limitation and the potential dilution or seniority of future financing instruments.
- Monitor the K2 secured debt, interest-rate exposure, 2024 maturity, final payment obligation, and covenant compliance.
- Evaluate whether the reported cash runway remains valid after incorporating ongoing losses, lease commitments, pipeline spending, license milestones, and other contractual obligations.